Nymox reports encouraging results from long term BPH study

The study evaluated symptomatic progress of US patients involved in the company’s two Phase I/II studies initiated in 2003. Patients treated with NX-1207 were followed-up on an unselected and as available basis and assessed for symptomatic improvement, treatment outcomes, and durability of efficacy 54 months after NX-1207 treatment. These subjects were last assessed at 42 months after treatment.

Overall, 75% of the patients in the new outcome study treated with NX-1207 reported no current drug treatment for their benign prostatic hyperplasia (BPH) and had a mean improvement of 11.1 points in AUA Symptom Score. In addition, 38% of the patients reported no other approved treatments at any time for their BPH since their original treatment with NX-1207, with a mean improvement of 9.8 points. This sustained improvement in BPH symptom score after NX-1207 treatment compares favorably to the 3.5 to five points reported in published studies of currently approved BPH drugs, which, unlike NX-1207 treatment, require uninterrupted, daily administration to be effective.

Paul Averback, CEO of Nymox, said: “This new data on NX-1207 showing sustained symptomatic improvement after 54 months provides further evidence of enduring benefits from NX-1207 treatment for BPH. NX-1207 thus far has had none of the well known sexual and other bothersome side effects of other BPH treatments.”